The invention pertains to dispersible tablets comprising as active ingredient 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4] triazol-1-yl] benzoic acid or pharmaceutically acceptable salt thereof in an amount of from 5 to 40% in weight by weight of the total tablet.DEFFEZ Karine...
The invention pertains to dispersible tablets comprising as active ingredient deferasirox 4-[3,5-bis(2hydroxyphenyl)-[1,2,4]triazol-l-yl]benzoic acid or pharmaceutically acceptable salt thereof in an amount of from 42% to 65% in weight by weight of the total tablet.C·博尚...
Do not chew or crush theExjade dispersible tablet,and do not swallow it whole. Place the tablet into a glass of apple juice, orange juice, or water and allow the tablet to disperse in the liquid. The tablet will not dissolve completely. Drink this mixture right away. To make sure you ...
Deferasirox is available in tablet form for oral administration. It is a yellowish powder that is soluble in water and has a molecular weight of 373.36 g/mol. Deferasirox is classified as a prescription medication and should only be used under the supervision of a healthcare professional. Common...
A simple stability indicating RP-HPLC assay method has been developed and validated for the determination of Deferasirox from tablet dosage form. Drugs were determined on a Hypresil BDS 150 x 4.6mm column packed with 5碌m particles. The optimized mobile phase was a 50: 50 (v/v) Buffer (1...
Deferasirox (DFX) is the newest among three different chelators available to treat iron overload in iron-loading anaemias, firstly released as Dispersible Tablets (DT) and more recently replaced by Film-Coated Tablets (FCT). In this retrospective observa
14. A process for the preparation of a coated deferasirox tablet, comprising the steps of: (i) mixing deferasirox or a pharmaceutically acceptable salt and at least one pharmaceutically acceptable excipient; (ii) wet-granulating the mixture obtained in step (i) in a high shear granulator; (iii...
PROBLEM TO BE SOLVED: To provide a dispersible tablet comprising, as an active ingredient effective as an iron chelating agent used in a patient requiring repeating blood transfusion, 4-[3, 5-bis(2-hydroxyphenyl)-[1, 2, 4] triazol-1-yl] benzoic acid (a compound I) or a pharmaceutically...
The invention pertains to dispersible tablets comprising as active ingredient 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid or pharmaceutically acceptable salt thereof in an amount of from 5 to 40% in weight by weight of the total tablet.CASSIERE, JEAN-PIERRE...
DEFERASIROX DISPERSIBLE TABLETPROBLEM TO BE SOLVED: To provide a dispersible tablet which is easily administered to an adult and a child requiring a repeat of blood transfusion and provides a daily administration amount of a pharmacological activity.DEFFEZ KARINEカリーヌドゥフェ...